Rapid Rx Quiz: Semaglutide

Mary L. Windle, PharmD

Disclosures

January 20, 2022

The STEP 8 trial compared the weight loss efficacy of high-dose semaglutide against liraglutide at its approved dose for obesity (3 mg) in patients with T2D. Patients had a body weight reduction of 15.8% with semaglutide vs 6.4% with liraglutide.

In STEP 2, the higher dose of semaglutide (2.4 mg) achieved slightly better glycemic control, reductions in cardiometabolic risk, and improved physical function relative to the standard dose.

The STEP 1 trial involved patients who were obese or overweight without diabetes. More than 86% in the semaglutide group lost at least 5% of their body weight. In STEP 2, the average body weight reduction with 2.4 mg of semaglutide in patients with diabetes was 9.64%.

The STEP 4 trial found that participants who continued to take semaglutide lost an additional 7.9% of their body weight from weeks 20 to 48. This resulted in a total 17.4% weight loss over the whole trial. Those who switched to placebo after 20 weeks regained an average 6.9%, giving a total weight loss of 5%.

Take a clinical quiz on weight loss.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....